HNSCC Clinical Trials in Boston, Massachusetts

5 studies are recruiting for hnscc in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

2. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

   Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   Adcendo ApS

   See if you can join NCT06597721 on ClinicalTrials.gov

3. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Boston, Massachusetts

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

4. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital - Dana Farber, Boston, Massachusetts

   Locations

   54 in total

   Run by

   Merus B.V.

   See if you can join NCT03526835 on ClinicalTrials.gov

5. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   9 in total

   Run by

   ImmVira Pharma Co. Ltd

   See if you can join NCT04370587 on ClinicalTrials.gov